Management of Severe Hypertriglyceridemia

Treatment Approach

For patients with severe hypertriglyceridemia (triglycerides ≥500 mg/dL), the American Heart Association recommends fenofibrate as the preferred first-line treatment to prevent acute pancreatitis, with a 30-50% triglyceride reduction 1, 2, 3
The American Diabetes Association explicitly states that statin plus fibrate combination therapy has not been shown to improve cardiovascular outcomes and is generally not recommended 2, 5
Fenofibrate reduces triglycerides by 30-50%, which is substantially more effective than the 10-30% reduction achieved with statins 2, 6, 4

The American Heart Association recommends icosapent ethyl 2 g twice daily for patients with fasting triglycerides 135-499 mg/dL, LDL-C 41-100 mg/dL, on statin therapy, with HbA1c <10%, and no history of pancreatitis, atrial fibrillation, or severe heart failure 1, 3
The REDUCE-IT trial demonstrated a 25% relative risk reduction in major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina) with icosapent ethyl versus placebo 7, 2, 5
Cardiovascular death was reduced by 20% (P=0.03), and the composite of cardiovascular death, nonfatal MI, or nonfatal stroke was reduced by 26% (P<0.001) 2, 5

When combined with statins, use lower statin doses to minimize myopathy risk, particularly in patients >65 years or with renal disease 2, 5, 4
Fenofibrate has a better safety profile than gemfibrozil when combined with statins 5, 4
Monitor creatine kinase levels and muscle symptoms 2, 5, 4
Adjust dose based on renal function 4

For patients with severe hypertriglyceridemia who also have cardiovascular risk, initiate fenofibrate to reduce triglycerides below 500 mg/dL, then optimize statin therapy to address LDL-C and cardiovascular risk, and finally add Vascepa 2 g twice daily if triglycerides remain 135-499 mg/dL after 3 months on statin therapy with controlled LDL-C 1, 2, 3, 4